Effekte von Cisplatin und Carboplatin auf verschiedene Biomarker im Urin

Goldstein, Kathi

dc.contributor.advisor	Blaschke, Sabine Prof. Dr.
dc.contributor.author	Goldstein, Kathi
dc.date.accessioned	2016-07-28T09:17:52Z
dc.date.available	2016-08-15T22:50:06Z
dc.date.issued	2016-07-28
dc.identifier.uri	http://hdl.handle.net/11858/00-1735-0000-0028-87DD-6
dc.identifier.uri	http://dx.doi.org/10.53846/goediss-5763
dc.language.iso	deu	de
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc	610	de
dc.title	Effekte von Cisplatin und Carboplatin auf verschiedene Biomarker im Urin	de
dc.type	doctoralThesis	de
dc.title.translated	Effects of Cisplatin and Carboplatin on different urinary biomarkers	de
dc.contributor.referee	Asif, Abdul Rahman PD Dr.
dc.date.examination	2016-08-08
dc.description.abstracteng	Cis- and Carboplatin are frequently part of a cytostatic therapy and have potential nephrotoxic side effects. Early detection of renal damage is of outmost clinical relevance to prevent acute renal failure. However, the standard clinical tests for detection of kidney injury - especially serum creatinine measurements - are insensitive and detect only advanced stages of injury. Therefore, a variety of urinary biomarkers is currently under evaluation to identify biomarkers for early detection of kidney injury. Most studies analyze only changes in one or a few biomarkers, thus information on a direct comparison of a larger number of different markers is limited. This study compares changes a variety of different renal biomarkers measured by clinical chemistry and Luminex-based technology. Markers of the proximal tubule (ßNAG, α1MG, ß2MG) reacted fastest to therapy with platin-derivates and may be eligible for early detection of renal damage. Increased levels of proximal (α1M, Kim-1) and glomerular (osteopontin) markers in the urine.of patients with diabetes may reflect a higher susceptibility to kidney damage. Further studies in larger cohorts have to evaluate clinical sensitivity and specificity of these urinary biomarkers.	de
dc.contributor.coReferee	Mausberg, Rainer Prof. Dr.
dc.subject.ger	Cisplatin	de
dc.subject.ger	Carboplatin	de
dc.subject.ger	Biomarker	de
dc.subject.ger	Nierenversagen	de
dc.subject.eng	Cisplatin	de
dc.subject.eng	Carboplatin	de
dc.subject.eng	Kidney injury	de
dc.subject.eng	biomarkers	de
dc.subject.eng	cytostatic therapy	de
dc.identifier.urn	urn:nbn:de:gbv:7-11858/00-1735-0000-0028-87DD-6-0
dc.affiliation.institute	Medizinische Fakultät	de
dc.subject.gokfull	Medizin (PPN619874732)	de
dc.subject.gokfull	Nephrologie	de
dc.description.embargoed	2016-08-15
dc.identifier.ppn	869468324

Dateien

Name:SUB_eDiss-Version (ohne Lebnslauf)pdf.pdf

Größe:1.920Mb

Format:PDF

Öffnen

Name:: SUB_eDiss-Version (ohne Lebnsl ...
Größe:: 1.920Mb
Format:: PDF

Öffnen

Das Dokument erscheint in:

Human- und Zahnmedizin [2872]

Zur Kurzanzeige